Carreras-Mora José, Simón-Ramón Clara, Vidal-Burdeus María, Rodríguez-Sotelo Laura, Sionis Alessandro, Giralt-Borrell Teresa, Izquierdo-Marquisá Andrea, Rodríguez-González Clara, Farré Núria, Cainzos-Achirica Miguel, Tizón-Marcos Helena, Garcia-Picart Joan, Milà-Pascual Laia, Vaquerizo Beatriz, Rivas-Lasarte Mercedes, Ribas-Barquet Núria
Department of Cardiology, Hospital del Mar, Barcelona, Spain
Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Heart. 2023 Oct 12;109(21):1602-1607. doi: 10.1136/heartjnl-2023-322690.
We evaluated the prognostic value of subclinical congestion assessed by lung ultrasound (LUS) in patients admitted for ST segment elevation myocardial infarction (STEMI).
This was a multicentre study that prospectively enrolled 312 patients admitted for STEMI without signs of heart failure (HF) at admission. LUS was performed during the first 24 hours after revascularisation and classified patients as having either wet lung (three or more B-lines in at least one lung field) or dry lung. The primary endpoint was a composite of acute HF, cardiogenic shock or death during hospitalisation. The secondary endpoint was a composite of readmission for HF or new acute coronary syndrome or death during 30-day follow-up. Zwolle score was calculated in all patients to assess predictive improvement by adding the result of the LUS to this score.
14 patients (31.1%) in the wet lung group presented the primary endpoint vs 7 (2.6%) in the dry lung group (adjusted RR 6.0, 95% CI 2.3 to 16.2, p=0.007). The secondary endpoint occurred in five patients (11.6%) in the wet lung group and in three (1.2%) in the dry lung group (adjusted HR 5.4, 95% CI 1.0 to 28.7, p=0.049). Addition of LUS improved the ability of the Zwolle score to predict the follow-up composite endpoint (net reclassification improvement 0.99). LUS showed a very high negative predictive value in predicting in-hospital and follow-up endpoints (97.4% and 98.9%, respectively).
Early subclinical pulmonary congestion identified by LUS in patients with Killip I STEMI at hospital admission is associated with adverse outcomes during hospitalisation and 30-day follow-up.
我们评估了通过肺部超声(LUS)评估的亚临床充血对ST段抬高型心肌梗死(STEMI)住院患者的预后价值。
这是一项多中心研究,前瞻性纳入了312例入院时无心力衰竭(HF)体征的STEMI患者。在血运重建后的最初24小时内进行LUS检查,并将患者分为肺湿(至少一个肺野有三条或更多B线)或肺干。主要终点是住院期间急性HF、心源性休克或死亡的复合终点。次要终点是30天随访期间因HF再次入院、新发急性冠状动脉综合征或死亡的复合终点。计算所有患者的兹沃勒评分,以评估将LUS结果加入该评分后预测能力的改善情况。
肺湿组14例患者(31.1%)出现主要终点,而肺干组为7例(2.6%)(调整后相对危险度6.0,95%可信区间2.3至16.2,p=0.007)。肺湿组5例患者(11.6%)出现次要终点,肺干组为3例(1.2%)(调整后风险比5.4,95%可信区间1.0至28.7,p=0.049)。加入LUS提高了兹沃勒评分预测随访复合终点的能力(净重新分类改善0.99)。LUS在预测住院和随访终点方面显示出非常高的阴性预测价值(分别为97.4%和98.9%)。
入院时LUS识别出的Killip I级STEMI患者早期亚临床肺充血与住院期间及30天随访期间的不良结局相关。